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Vania Fontani3,4, Carlo Ventura2,5 & Pier Andrea Serra6
Research for the use of physical means, in order to induce cell differentiation for new therapeutic 
strategies, is one of the most interesting challenges in the field of regenerative medicine, and then 
in the treatment of neurodegenerative diseases, Parkinson’s disease (PD) included. The aim of this 
work is to verify the effect of the radio electric asymmetric conveyer (REAC) technology on the PC12 
rat adrenal pheochromocytoma cell line, as they display metabolic features of PD. PC12 cells were 
cultured with a REAC regenerative tissue optimization treatment (TO-RGN) for a period ranging 
between 24 and 192 hours. Gene expression analysis of specific neurogenic genes, as neurogenin-1, 
beta3-tubulin and Nerve growth factor, together with the immunostaining analysis of the specific 
neuronal protein beta3-tubulin and tyrosine hydroxylase, shows that the number of cells committed 
toward the neurogenic phenotype was significantly higher in REAC treated cultures, as compared 
to control untreated cells. Moreover, MTT and Trypan blue proliferation assays highlighted that 
cell proliferation was significantly reduced in REAC TO-RGN treated cells. These results open new 
perspectives in neurodegenerative diseases treatment, particularly in PD. Further studies will be 
needed to better address the therapeutic potential of the REAC technology.
Previous studies, conducted using the radio electric asymmetric conveyor (REAC) technology, have 
shown that this technology is able to induce neurogenic cell differentiation both in cultures of murine 
embryonic cells1 and in differentiated human cells, such as fibroblasts2 and adipocytes3. In addition, 
the REAC technology has been shown to effectively counteract cell aging4–6, a process often related to 
neurodegenerative diseases as Parkinson’s disease (PD). To better dissect and understand the potential 
of the REAC treatments in PD, we chose a PC 12 cellular model. This model was widely used to study 
neuron functions and to understand the physiology of central dopamine (DA) neurons. Therefore, we 
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think this study can provide useful information and pave the way to future possible application of REAC 
technology in the treatment of PD.
Results
REAC TO-RGN exposure primes cell commitment toward a neurogenic phenotype. Figure 1 
shows the expression of the neurogenic phenotype associated genes β 3-tubulin and neurogenin-1, and 
nerve growth factor (NGF) in PC12 cells exposed to REAC TO-RGN for 24 h (1 day) to 192 h (8 days); 
β 3-tubulin and neurogenin-1 were expressed both in control and in REAC TO-RGN treated cells. But 
after 96 hours REAC TO-RGN treated cells exhibited significantly higher levels of β 3-tubulin, as com-
pared to control cells; on the other hand neurogenin-1 mRNA levels were significantly higher in REAC 
TO-RGN treated as compared to untreated cells, just after 24 hours of exposure, and were retained higher 
even after 96 hours of treatment (Fig. 1). The same figure shows also that the expression of Nerve Growth 
factor (NGF), a known regulator of neuritogenesis in PC12 cells7 was significantly increased in REAC 
TO-RGN treated than in untreated cells, throughout the culturing period. The same figure shows that 
also the expression of tyrosine hydroxylase, a key enzyme in catecholamine biosynthesis was induced 
by REAC treatment (Fig. 1). Figure 2 shows the western blotting analysis of β 3-tubulin, neurogenin 1, 
NGF and tyrosine hydroxylase, all of these proteins were significantly increased in REAC treated cells, 
confirming what previously observed by gene expression analysis (Fig. 1).
REAC TO-RGN exposure induces the appearance of neuron-like cells. Immunocytochemistry 
revealed that both untreated and REAC TO-RGN treated PC12 cells expressed the neuronal marker β -3 
tubulin and the tyrosine hydroxylase, the rate-limiting enzyme of catecholamine biosynthesis, but in cells 
REAC TO-RGN treated both the number of positively stained cells, and the intensity of fluorescence, 
revealed a higher expression of both proteins, confirming what previously observed in β -3 tubulin gene 
expression analysis (Fig. 3).
The effect of REAC TO-RGN on the proliferation of PC12 cells. Figure 4 (Panel a) shows both 
staining results from MTT assay and Trypan Blue assay at the beginning of the experiment (24 h) and at 
the end of it (192 h). At 24 h, no statistical differences in cell number were detected, neither in control 
cells nor in REAC TO-RGN treated cells. After 192 hours of treatment, REAC TO-RGN treated cultures 
displayed a significantly lower number of cells as compared to untreated cells. Measuring the protein 
content in controls and REAC TO-RGN treated cells, we found that there was no difference in the 
average content of proteins (data no shown), thus we calculated the amount of proteins per cell (Fig. 4, 
panel b). In control group, this ratio (protein content divided by cell number) showed a not statistically 
significant decrease during the first five days and then stabilized over the next three, when cells reached 
the confluence. In REAC TO-RGN exposed cells the amount of proteins per cell statistically increased 
of about 25% from the third to last day. This data suggest a higher level in protein synthesis and cellular 
differentiation, as shown by the increase in neurite length by the fourth day in treated cells compared 
to untreated cells. Indeed starting from the fourth day of treatment these cells have been shown cellular 
processes longer (P < 0.05) than those eventually present in the untreated cells (Fig. 4, panel c, d).
Discussion
The use of PC12 cells as a model for the study of dopaminergic neurons, and also as a possible therapeu-
tic tool in Parkinson’s disease8,9 has long been investigated. As known, the reduction of TH expression in 
the substantia nigra pars compacta of parkinsonian patients is a constant anatomo-pathological finding, 
while the striatal availability of DA is related to nigral TH expression. Despite the cell culture studies pro-
posed in this manuscript are not conclusive for PD treatment and further studies are required in animal 
models of Parkinsonism (i.e. rats treated with MPTP or TAT-alpha-synuclein)10,11, the obtained data are 
suggestive of an enhancement of DA biosynthesis and availability. Studies are in progress for determining 
the effect of REAC treatment on PC12 cells DA biosynthesis and metabolism. Furthermore, the research 
for the use of physical means, in order to induce cell differentiation for new therapeutic strategies, is 
one of the most interesting challenges in the field of regenerative medicine, and then in the treatment of 
neurodegenerative diseases, Parkinson’s disease (PD) included. In this work, we have demonstrated that 
PC12 REAC TO-RGN exposure primes cell commitment toward a neurogenic phenotype and induce 
the appearance of neuron-like cells. Previous results clearly demonstrated that RGN treatment protocols 
was able to induce cell differentiation toward neural phenotype1–3. In the present study, we observed 
the increase in neuritogenesis, together with the significantly higher amount of protein synthesis in 
REAC TO-RGN treated cells as compared to control untreated. This discover is supported by the gene 
expression analysis, which highlights higher mRNA levels of neurogenin-1, an important transcription 
factor regulating neurogenesis12,13 and consequently of β 3-tubulin, a neural phenotype specific marker14. 
The expression of this neural specific protein, as assessed by immunofluorescence and western blotting 
analysis, was also increased in REAC TO-RGN treated cells, confirming the gene expression analysis. 
These observations are further inferred by the increased expression of NGF observed in REAC TO-RGN 
exposed cells. Another interesting aspect revealed in this study, related to the increase of NGF, is the 
anti-proliferative effect in REAC TO-RGN -treated cells. NGF has been widely described as a regulator 
of PC12 proliferation leading to a decrease in proliferation rate, by inducing cell cycle arrest in G0/G1 
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Figure 1. Effect of REAC TO-RGD treatment on the expression of neuritogenesis regulating genes in PC12 
cells. Cells were exposed from 1 (24 h) to 8 days (192 h) in the absence or presence (darker bars) of REAC 
TO-RGN. The amounts of β 3 tubulin, neurogenin-1 NGF and tyrosine hydroxylase (TH) mRNA from 
REAC TO-RGN treated or untreated cells were normalized to GAPDH, and the mRNA expression of REAC 
TO-RGN treated cells was plotted at each time point as fold of change relative to the expression in PC12 
untreated cells cultured for 24 hours after plating (named ND) defined as 1 (mean ± S.E.; n = 6). All the 
REAC TO-RGN treated cells at each time point were significantly different from each control untreated cells 
(mean ± S.E.; n = 6; P < 0.05).
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phase15 and their terminal differentiation within the neural lineage16. Interestingly the analysis of cell 
viability clearly demonstrate an antiproliferative effect of REAC TO-RGN treatment on PC12 cells, while 
we previously demonstrated no viability reduction in human skin-derived fibroblasts2 and in human 
adipocyte derived stem cells3 exposed to REAC treatment. This event determinate an evident decrease 
in the number of PC12 tumor cells, presumably related to the NGF-induced neural differentiation. The 
data collected in this study, confirm the differentiation effect of the REAC TO-RGN treatments, pre-
viously observed in the induction of reprogramming and differentiation processes in normal cells1–3,5. 
Furthermore, the results obtained in this study, might suggest a possible future use of REAC treatments, 
as adjuvants in PD, even though further studies will be needed.
Figure 2. Effect of REAC TO-RGD treatment on the expression of neuritogenesis associated proteins in 
PC12 cells. Total lysates were isolated from PC12 cells, exposed for 24, 48, or 72 hours and for 7 days in the 
absence (− R) or presence of REAC (+ R). Samples were analyzed by Western blot, using antisera against 
tyrosine hydroxylase (TH), NGF, neurogenin 1 (NGN), ß-3 tubulin and GAPDH. The sizes of the bands 
were determined using prestained marker proteins. The data presented are representative of five separate 
experiments. Two different membranes were incubated with antirabbit (NGF ,GAPDH) or antimouse (β 
Tubulin isotype III) or antigoat (Neurogenin).
Figure 3. REAC TO-RGN induces PC12 differentiation toward neural phenotype. Expression of β -3-tubulin 
and Tyrosine Hydroxylase were assessed in cells cultured in the absence or presence of REAC TO-RGN 
treatment, for 168 h (7 days). Nuclei are labeled with DAPI (blue). Scale bars are 40 μ m. Representative of 
five separate experiments. For each differentiation marker, fields with the highest yield of positively stained 
cells are shown.
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Materials and Methods
Reagents and solutions. All chemicals were analytical reagent grade and were used as supplied. 
Trypan Blue solution 0.4%, Thiazolyl Blue Tetrazolium Blue (MTT) powder, were purchased from Sigma 
(Milano, Italy). Dulbecco’s modified Eagle’s medium F12, horse serum (HS) and fetal bovine serum (FBS) 
and Streptomycin/Penicillin was bought by LIFE Technologies (Milano, Italy).
The phosphate-buffered saline (PBS) solution used for cell cultures was made using NaCl (137 mM), 
KCl (2.7 mM), Na2HPO4 (8.1 mM), KH2PO4 (1.47 mM), CaCl2 (1.19 mM), MgCl2 (0.54 mM), and glu-
cose (7.5 mM) and then adjusted to pH 7.4: all reagents used for PBS solution were purchased from 
Sigma (Monza, Italy).
Cell culture. PC12 cells were kept at 37 °C in 100 mm plastic culture plates in Dulbecco’s modified 
Eagle’s medium F12 (DMEM) enhanced with 10% HS, 5% FBS and a 1% of Streptomycin/Penicillin, 
in a humidified atmosphere of 5% CO2/ 95% air, as previously shown17. Cells were treated with REAC 
TO-RGN for 24, 48, 72, 96, 120, 144, 168 and 192 hours. Each sample was processed for MTT and Tripan 
Blue assay and for each sample protein content was evaluated by means of Lowry method18.
Cell Viability Assays - MTT Assay. PC12 cells were treated or not (control) for 24 h and 8 days 
(192 h) with REAC TO-RGN in 24-well plates (60 × 103 cells per well). Experiments were done in tripli-
cate. Cell viability was assessed by the 3-(4, 5-dimethyl- thiazol-2-yl)-2, 5, diphenyltetrazolium bromide 
(MTT) assay19. In this assay, viable cells convert the soluble dye MTT to insoluble (in aqueous media) 
blue formazan crystals. At the beginning of each experiment, and at selected intervals, cell number was 
determined in triplicate wells. Briefly, 1 mg of MTT (200 μ l of a 5 mg/ml stock solution in phosphate 
buffered saline (PBS)) was added per ml of medium and the cultures allowed to incubate at 37 °C or 
4 h. The MTT was removed and the cells rinsed with PBS and centrifuged at 4000 rpm for 20 minutes. 
Thus the supernatant was discarded, the pellet dissolved in 2 ml isopropanol and after centrifugation at 
Figure 4. Panel a - MTT analysis and trypan blue staining and morphological changes in REAC TO-
RGN treated PC12 cells. MTT (white bars) and Trypan blue (darker bars) cell proliferation analysis were 
performed 24 and 192 hours after culturing control and REAC TO-RGN treated cells. Panel b - Intracellular 
proteins quantification by Lowry method. It shows that the amount of total protein per cell is increased 
after the REAC TO-RGN treatment. Panel c - Microphotographies under a phase-contrast microscope show 
untreated cells (control) and REAC TO-RGN treated cells with neurites at 96 hours. Representative of five 
separate experiments. Panel d - Neurite length measurement. The morphological changing as neurite growth 
is shown in control and REAC TO-RGN treated cells after 96 and 192 hours.
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4000 rpm for 5 min the color was read at 600 nm using a Bauty Diagnostic Microplate Reader. A standard 
curve was created utilizing different concentrations of cells at the beginning of every experiment. Before 
the experiments, PC12 cells were prepared in the cell laboratory of Pharmacology section and then 
transferred to the cell laboratory of Biochemistry. Only the treatment groups were subjected to REAC 
exposure. Subsequently, the PC12 cells were processed in both laboratories mentioned above by means 
of double-blind control procedures.
Trypan-Blue Staining. For each experiment, PC12 cells were exposed for 24 h and 192 h (8 days) to 
REAC TO-RGN in 24-well plates (60 × 103 cells per well). Control groups were maintained in the same 
culture condition without REAC TO-RGN exposure. Experiments were done in triplicate.
For evaluating cell survival, the trypan blue (0.4%) exclusion assay, based on the capability of viable 
cells to exclude the dye, was used. As viable PC12 cells are capable of maintaining membrane integ-
rity and preventing trypan blue dye to pass through the cell membrane, cells with damaged membrane 
appeared blue due to the accumulation of dye and were taken as dead cells. For trypan blue staining, 
10 μ l trypan blue solution and 90 μ l of cells from each sample were incubated for 1 min. Unstained live 
cells were counted with Burker’s chamber.
Description of Radio Electric Asymmetric Conveyer (REAC) technology. The REAC is an 
innovative-patented technology for bio-stimulation and/or bio-enhancement techniques. The REAC 
device generates an emission of microwaves of very weak intensity. The peculiarity of REAC technology 
is not the emission, but the particular physic link between the device and the patient’s body. The asym-
metric conveyer-probe (ACP) represents this link. The tailored ACP applied on cell cultures or patient’s 
body makes possible create a radio electric circuit in combination with the local electrical environment of 
the cell cultures or tissues, to concentrate the induced radio electric microcurrents inner the cell cultures 
or tissues to be treated.
The ACP provides an electrical tension reference in the cell cultures or in the point of the body where 
it is applied and acts therefore as a kind of pole of attraction. The electrical tension reference is fixed and 
independent of the applied load (the characteristics of the tissues in treatment). For this phenomenon, 
the radio electric micro currents induced in the body are conveyed by the ACP in the point of applica-
tion. Thanks to the radio electric microcurrents asymmetrically conveyed in the body, REAC technology 
is able to normalize currents flows existing in the cell cultures or human body, when these were reduced 
in quantity and altered in the transmission within the tissues. The REAC electromagnetic quantities have 
been measured with the spectrum analyzer Tektronix model 2754p (TekNet Electronics, Inc., Alpharetta, 
GA, USA), orienting the receiving antenna for maximum signal. With cell cultures at a distance of 35 cm 
from the 2.4 GHz. emitter, we measured a radiated power of approximately 400 μ W/m2. Electric field 
E = 0.4 V/m, magnetic field = 1 mA/m. Specific absorption rate (SAR) = 0.128 μ W/g.
REAC tissue optimization - regenerative treatments (TO-RGN). REAC tissue optimization 
(TO) regenerative treatments (RGN) includes a set of treatment protocols1–5,20 which are carried out by 
the ACP immersed in the medium of the cell culture or covering the treated area with ACP. The REAC 
TO-RGN has been administered 168 hours without interruption. The REAC device used in this study 
(B.E.N.E Bio enhancer - Neuro enhancer, ASMED, Florence, Italy) is specific for regenerative treatments.
Cell Differentiation. PC12 cells (105 cells/mL) were differentiated by REAC TO-RGN exposure as 
previously described2. Briefly, PC12 cells growing in 100-mm culture dishes were treated with REAC 
TO-RGN for 24, 48, 72, 96, 120, 144, 168, and 192.
Morphological analysis. Microphotographs of PC12 cells from untreated cultures (control) and from 
treated ones were taken after 96 hours of REAC TO-RGN treatment to track any morphologic changes. 
Collected images were loaded into ImageJ (National Institute of Health, USA) and analyzed to measure 
neurite length.
Gene expression analysis. PC12 cells were cultured in the absence or presence of REAC TO-RGN 
for 24, 48, 72, 96, 120, 144, 168, 196 hours. Total RNA was isolated using Trizol reagent according to 
the manufacturer’s instructions (Invitrogen). Total RNA was dissolved in RNAase-free water and, for 
RT- PCR, cDNA was synthesized in a 50-μ l reaction volume with 1 μ g of total RNA using Superscript 
Vilo cDNA synthesis kit, according to the manufacturer’s instruction (Life Technologies). Quantitative 
real-time PCR was performed using an iCycler Thermal Cycler (Bio-Rad). Two μ l of cDNA were ampli-
fied in 50-μ l reactions using Platinum Supermix UDG (Invitrogen), 200 nM of each primer, 10 nM flu-
orescein (BioRad), and SYBR Green. After an initial denaturation step at 94 °C for 10 min, temperature 
cycling was initiated. Each cycle consisted of 94 °C for 15 s, 55– 59 °C for 30 s, and 60 °C for 30 s, the flu-
orescence being read at the end of this step. Primers used for the analysis of neurogenesis (Neurogenin-1 
and beta 3 tubulin) and nerve growth factor (NGF) were specific and spanning exons, are reported in 
Fig. 5.
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To evaluate the quality of product of real-time PCR assays, melting curve analysis was per-formed 
after each assay. Relative expression was determined using the “delta-CT method” with glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) as reference gene21.
Immunocytochemistry. Cells were cultured for 7 days with or without REAC TO-RGN treatment 
on glass coverslips coated with 0.2% type III Collagen at low density to permit visualization of individual 
cells. After 7 days, cells were fixed for 20 min in 4% paraformaldehyde (Life Technologies). The cells were 
washed 3 times with phosphate-buffered saline (PBS) with 0.1% Triton X-100, and then incubated with 
the primary antibody overnight at 4 °C. The cells were then incubated with the secondary antibody. To 
verify differentiation toward a dopaminergic neuronal phenotype, the following antibodies were used: 
mouse monoclonal anti-ß-3 tubulin (Santa Cruz Biotechnology); rabbit polyclonal anti- tyrosine hydroxy-
lase (Santa Cruz Biotechnology). The secondary antibodies used in this study were: Alexa 594-conjugated 
goat-anti-rabbit IgG (1:400; Life Technologies) and anti-Mouse IgG (whole molecule) − TRITC antibody 
produced in goat (Sigma-Aldrich). All microscopy was performed with a Leica confocal microscope 
(LEICA TCSSP5). DNA was visualized with 1μ g/ml 4’,6-diamidino-2-phenylindole (DAPI).
Western blotting. Cells were cultured in the presence or absence of REAC for 24, 48, or 72 hours and 
for 7 days. Total cell lysates from PC12 were electrophoresed on 10% Novex Tris-glycine polyacrylamide 
gels (Invitrogen) in MOPS sodium dodecyl sulfate running buffer using an XCell SureLock™ Mini-Cell 
(Invitrogen) according to the instructions provided by the manufacturer. After protein transfer to poly-
vinylidenedifluoride membranes (Invitrogen), and membrane saturation and washing, immunoreaction 
was carried out for one hour at room temperature in the presence of the primary antibody, antisera 
against β Tubulin isotype III (Cell Signaling technology), NGF (Santa Cruz Biotechnology, Inc.), TH 
(Santa Cruz Biotechnology, Inc), Neurogenin (Santa Cruz Biotechnology, Inc), and GAPDH (Santa Cruz 
Biotechnology, Inc.) diluted to 1:1000. After additional washing, membranes were incubated with anti-
rabbit (NGF ,GAPDH) or antimouse (β Tubulin isotype III) or antigoat (Neurogenin). Targeted protein 
expression was assessed using a chemoluminescence detection system (ECL Western blotting detection 
reagents were from Amersham Biosciences Corporation, Piscataway, NJ, USA).
Statistical analysis. Statistical analysis was performed using the software package SPSS (Statistical 
Package for Social Science) version 13.0. For this study, were applied to the data collected, the nonpara-
metric Kruskal-Wallis test, Jonckheere-Terpstra and Wilcoxon test: the first two to assess the adequacy of 
treatment, i.e. the differences (DeltaDelta CT) between the data collected in treated and in control. The 
Wilcoxon test was applied to assess the adequacy of the data of each group in the different observation 
times. The tests and results with p < 0.05 were considered statistically significant. For the adequacy of the 
data, the results of the Wilcoxon test showed a high statistical significance in all observations (Asymp. Mr. 
2-tailed < 0.05). For the congruity of the treatments, the tests were applied to 3 sets, in eight moments 
of observation, after the treatment and control conditions. The analysis shows a statistical significance 
p < 0.05 in the treated (Kruskal-Wallis test: Asymp. Sig. 2-tailed < 0.417 and Jonckheere-Terpstra test: 
Asymp. Sig. 2-tailed < 0.295) and p > 0.05 in controls. (Kruskal-Wallis test: Asymp. Sig. 2-tailed = 0.7 
and Jonckheere-Terpstra test: Asymp. Sig. 2-tailed > 0.75).
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